GLP-1

Make a delay and accumulation of outstanding tasks Full stop
Biotech

Terns mothballs obesity program after phase 2 data fall short

The phase 2 trial delivered a mix of weight loss and tolerability that fell short of expectations and evidence the asset causes liver injuries.
Nick Paul Taylor Oct 22, 2025 7:15am
Graphic image of an arrow nailing the bullseye of a target

Lilly pads oral GLP-1 case with pair of phase 3 diabetes wins

Oct 15, 2025 9:48am
Inside the small intestine

Fractyl delivers data on its device for GLP-1 weight maintenance

Sep 30, 2025 12:10pm
weight loss scale weigh measure tape obesity overweight

Pfizer’s new prize Metsera touts 14% weight loss for GLP-1

Sep 30, 2025 6:40am
weight loss drugs obesity

Roche's obesity ambition not reliant on one megablockbuster

Sep 23, 2025 7:45am
Measuring tape on top of cash

Pfizer inks $4.9B Metsera buyout to beef up obesity pipeline

Sep 22, 2025 7:47am